These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 23905402)

  • 1. [Buprenorphine transdermal patch (Norspan tape)].
    Hamaguchi S; Ikeda T
    Masui; 2013 Jul; 62(7):799-807. PubMed ID: 23905402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buprenorphine: revisiting the efficacy of transdermal delivery system.
    Kitzmiller JP; Barnett CJ; Steiner NS; Stoicea N; Kamar N; Luzum JA; Mikulik E; Bergese SD
    Ther Deliv; 2015; 6(4):419-22. PubMed ID: 25996041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching from high doses of pure μ-opioid agonists to transdermal buprenorphine in patients with cancer: a feasibility study.
    Lundorff L; Sjøgren P; Hansen OB; Jonsson T; Nielsen PR; Christrup L
    J Opioid Manag; 2013; 9(4):255-62. PubMed ID: 24353018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buprenorphine for chronic pain.
    Calderon R; Copenhaver D
    J Pain Palliat Care Pharmacother; 2013 Dec; 27(4):402-5. PubMed ID: 24245573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Transdermal fentanyl patch for the treatment of chronic intractable pain].
    Ibuki T
    Masui; 2013 Jul; 62(7):784-90. PubMed ID: 23905400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine.
    Kress HG
    Eur J Pain; 2009 Mar; 13(3):219-30. PubMed ID: 18567516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain.
    Mitra F; Chowdhury S; Shelley M; Williams G
    Pain Med; 2013 Jan; 14(1):75-83. PubMed ID: 23320402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine 5, 10 and 20 μg/h transdermal patch: a review of its use in the management of chronic non-malignant pain.
    Plosker GL
    Drugs; 2011 Dec; 71(18):2491-509. PubMed ID: 22141389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The unique role of transdermal buprenorphine in the global chronic pain epidemic.
    Pergolizzi JV; Scholten W; Smith KJ; Leighton-Scott J; Willis JC; Henningfield JE
    Acta Anaesthesiol Taiwan; 2015 Jun; 53(2):71-6. PubMed ID: 26205326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdermal buprenorphine in clinical practice--a post-marketing surveillance study in 13,179 patients.
    Griessinger N; Sittl R; Likar R
    Curr Med Res Opin; 2005 Aug; 21(8):1147-56. PubMed ID: 16083522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials.
    Likar R; Kayser H; Sittl R
    Clin Ther; 2006 Jun; 28(6):943-52. PubMed ID: 16860176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus.
    Pergolizzi JV; Mercadante S; Echaburu AV; Van den Eynden B; Fragoso RM; Mordarski S; Lybaert W; Beniak J; Orońska A; Slama O;
    Curr Med Res Opin; 2009 Jun; 25(6):1517-28. PubMed ID: 19435402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clarification on transdermal buprenorphine.
    Dankiewicz EH; Haddox JD
    J Pain Palliat Care Pharmacother; 2014 Dec; 28(4):415-6. PubMed ID: 25348227
    [No Abstract]   [Full Text] [Related]  

  • 16. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
    Wirz S; Wittmann M; Schenk M; Schroeck A; Schaefer N; Mueller M; Standop J; Kloecker N; Nadstawek J
    Eur J Pain; 2009 Aug; 13(7):737-43. PubMed ID: 18977159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Post marketing surveillance study with an analgesic (transdermal buprenorphine patch) in patients with moderate to severe chronic pain].
    Tschirner M; Ritzdorf I; Brünjes R
    MMW Fortschr Med; 2008 Sep; 150 Suppl 3():142-8. PubMed ID: 19025217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High dose transdermal buprenorphine for moderate to severe pain in spanish pain centres--a retrospective multicenter safety and efficacy study.
    Barutell C; Camba A; González-Escalada JR; Rodríguez M;
    Pain Pract; 2008; 8(5):355-61. PubMed ID: 18662364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine 5, 10 and 20 μg/h transdermal patch: a guide to its use in chronic non-malignant pain.
    Plosker GL; Lyseng-Williamson KA
    CNS Drugs; 2012 Apr; 26(4):367-73. PubMed ID: 22369187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transdermal buprenorphine (Butrans) for chronic pain.
    Med Lett Drugs Ther; 2011 Apr; 53(1362):31-2. PubMed ID: 21502936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.